お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
お問い合わせ
会社概要
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
957112

腫瘍学分子診断の世界市場

Oncology Molecular Diagnostics
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 287 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.74円

ご注意：Single user licenseはDRM（デジタル著作権管理システム）付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

腫瘍学分子診断の世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 287 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の腫瘍学分子診断の市場規模は、分析期間（2020年～2027年）に11.2％のCAGRで成長する見通しで、2020年の17億米ドルから2027年には36億米ドルに達すると予測されています。当レポートで分析されているセグメントの1つである乳癌は、分析期間中に8.7％の年率で成長し、9億30万米ドルに達すると予測されています。

当レポートは、世界の腫瘍学分子診断市場について調査しており、市場シェア、動向や見通し、成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • Abbott Laboratories
  • Bayer Healthcare AG
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Cepheid, Inc.
  • Danaher Corporation
  • Hologic, Inc.
  • Leica Biosystems Inc.
  • Qiagen NV
  • Roche Diagnostics (Schweiz) AG
  • Siemens Healthineers
  • Sysmex Corporation

目次

I. イントロダクション、調査手法、調査範囲

II. エグゼクティブサマリー

  • 市場概要
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
  • 動向と成長要因
  • 世界市場の見通し

III. 市場分析

  • 地域別市場分析
  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

IV. 競合

  • 企業プロファイル：42社
目次
Product Code: MCP13704

Abstract:

Global Oncology Molecular Diagnostics Market to Reach $3.6 Billion by 2027

Amid the COVID-19 crisis, the global market for Oncology Molecular Diagnostics estimated at US$1.7 Billion in the year 2020, is projected to reach a revised size of US$3.6 Billion by 2027, growing at a CAGR of 11.2% over the analysis period 2020-2027. Breast Cancer, one of the segments analyzed in the report, is projected to record a 8.7% CAGR and reach US$900.3 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Colorectal Cancer segment is readjusted to a revised 14.5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $490.5 Million, While China is Forecast to Grow at 14.9% CAGR

The Oncology Molecular Diagnostics market in the U.S. is estimated at US$490.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$669.6 Million by the year 2027 trailing a CAGR of 14.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.9% and 9.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.8% CAGR.

Prostate Cancer Segment to Record 12.5% CAGR

In the global Prostate Cancer segment, USA, Canada, Japan, China and Europe will drive the 11.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$233.6 Million in the year 2020 will reach a projected size of US$506.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$533.5 Million by the year 2027, while Latin America will expand at a 14% CAGR through the analysis period.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories
  • Bayer Healthcare AG
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Cepheid, Inc.
  • Danaher Corporation
  • Hologic, Inc.
  • Leica Biosystems Inc.
  • Qiagen NV
  • Roche Diagnostics (Schweiz) AG
  • Siemens Healthineers
  • Sysmex Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Oncology Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 3: World 15-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2018 & 2027
    • TABLE 4: World Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 6: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
    • TABLE 7: World Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 9: World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
    • TABLE 10: World Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 12: World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
    • TABLE 13: World Current & Future Analysis for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 15: World 15-Year Perspective for Cervical Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
    • TABLE 16: World Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 18: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
    • TABLE 19: World Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 21: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
    • TABLE 22: World Current & Future Analysis for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 24: World 15-Year Perspective for Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
    • TABLE 25: World Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 27: World 15-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 28: USA Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 29: USA Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 30: USA 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 31: USA Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 32: USA Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 33: USA 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • CANADA
    • TABLE 34: Canada Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 35: Canada Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 36: Canada 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 37: Canada Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 38: Canada Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 39: Canada 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • JAPAN
    • TABLE 40: Japan Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 41: Japan Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 42: Japan 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 43: Japan Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 44: Japan Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 45: Japan 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • CHINA
    • TABLE 46: China Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 47: China Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 48: China 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 49: China Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 50: China Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 51: China 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • EUROPE
    • TABLE 52: Europe Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 53: Europe Historic Review for Oncology Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 54: Europe 15-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2018 & 2027
    • TABLE 55: Europe Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 56: Europe Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 57: Europe 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 58: Europe Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 59: Europe Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 60: Europe 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • FRANCE
    • TABLE 61: France Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 62: France Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 63: France 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 64: France Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 65: France Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 66: France 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • GERMANY
    • TABLE 67: Germany Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 68: Germany Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 69: Germany 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 70: Germany Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 71: Germany Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 72: Germany 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • ITALY
    • TABLE 73: Italy Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 74: Italy Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 75: Italy 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 76: Italy Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 77: Italy Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 78: Italy 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • UNITED KINGDOM
    • TABLE 79: UK Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 80: UK Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 81: UK 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 82: UK Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 83: UK Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 84: UK 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • SPAIN
    • TABLE 85: Spain Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 86: Spain Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 87: Spain 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 88: Spain Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 89: Spain Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 90: Spain 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • RUSSIA
    • TABLE 91: Russia Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 92: Russia Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 93: Russia 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 94: Russia Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 95: Russia Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 96: Russia 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • REST OF EUROPE
    • TABLE 97: Rest of Europe Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 98: Rest of Europe Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 99: Rest of Europe 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 100: Rest of Europe Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 101: Rest of Europe Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 102: Rest of Europe 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • ASIA-PACIFIC
    • TABLE 103: Asia-Pacific Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 104: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 105: Asia-Pacific 15-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2018 & 2027
    • TABLE 106: Asia-Pacific Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 107: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 108: Asia-Pacific 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 109: Asia-Pacific Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 110: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 111: Asia-Pacific 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • AUSTRALIA
    • TABLE 112: Australia Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 113: Australia Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 114: Australia 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 115: Australia Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 116: Australia Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 117: Australia 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • INDIA
    • TABLE 118: India Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 119: India Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 120: India 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 121: India Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 122: India Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 123: India 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • SOUTH KOREA
    • TABLE 124: South Korea Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 125: South Korea Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 126: South Korea 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 127: South Korea Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 128: South Korea Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 129: South Korea 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 130: Rest of Asia-Pacific Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 131: Rest of Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 132: Rest of Asia-Pacific 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 133: Rest of Asia-Pacific Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 134: Rest of Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 135: Rest of Asia-Pacific 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • LATIN AMERICA
    • TABLE 136: Latin America Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 137: Latin America Historic Review for Oncology Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 138: Latin America 15-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2018 & 2027
    • TABLE 139: Latin America Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 140: Latin America Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 141: Latin America 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 142: Latin America Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 143: Latin America Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 144: Latin America 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • ARGENTINA
    • TABLE 145: Argentina Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 146: Argentina Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 147: Argentina 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 148: Argentina Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 149: Argentina Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 150: Argentina 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • BRAZIL
    • TABLE 151: Brazil Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 152: Brazil Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 153: Brazil 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 154: Brazil Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 155: Brazil Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 156: Brazil 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • MEXICO
    • TABLE 157: Mexico Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 158: Mexico Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 159: Mexico 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 160: Mexico Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 161: Mexico Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 162: Mexico 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • REST OF LATIN AMERICA
    • TABLE 163: Rest of Latin America Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 164: Rest of Latin America Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 165: Rest of Latin America 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 166: Rest of Latin America Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 167: Rest of Latin America Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 168: Rest of Latin America 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • MIDDLE EAST
    • TABLE 169: Middle East Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 170: Middle East Historic Review for Oncology Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 171: Middle East 15-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2018 & 2027
    • TABLE 172: Middle East Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 173: Middle East Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 174: Middle East 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 175: Middle East Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 176: Middle East Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 177: Middle East 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • IRAN
    • TABLE 178: Iran Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 179: Iran Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 180: Iran 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 181: Iran Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 182: Iran Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 183: Iran 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • ISRAEL
    • TABLE 184: Israel Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 185: Israel Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 186: Israel 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 187: Israel Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 188: Israel Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 189: Israel 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • SAUDI ARABIA
    • TABLE 190: Saudi Arabia Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 191: Saudi Arabia Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 192: Saudi Arabia 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 193: Saudi Arabia Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 194: Saudi Arabia Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 195: Saudi Arabia 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 196: UAE Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 197: UAE Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 198: UAE 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 199: UAE Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 200: UAE Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 201: UAE 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • REST OF MIDDLE EAST
    • TABLE 202: Rest of Middle East Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 203: Rest of Middle East Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 204: Rest of Middle East 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 205: Rest of Middle East Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 206: Rest of Middle East Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 207: Rest of Middle East 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027
  • AFRICA
    • TABLE 208: Africa Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 209: Africa Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 210: Africa 15-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer and Other Disease Types for the Years 2012, 2018 & 2027
    • TABLE 211: Africa Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 212: Africa Historic Review for Oncology Molecular Diagnostics by Segment - Instruments, Reagents and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 213: Africa 15-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Instruments, Reagents and Other Segments for the Years 2012, 2018 & 2027

IV. COMPETITION

  • Total Companies Profiled: 44
株式会社グローバルインフォメーション
電話
044-952-0102
9:00-18:00 (土日・祝日を除く)
© Copyright 1996-2021, Global Information, Inc. All rights reserved.